- Home
- VLGEA vs YMAB Comparison
VLGEA vs YMAB Comparison
Compare VLGEA & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- YMAB
- Stock Information
- Founded
- VLGEA 1937
- YMAB 2015
- Country
- VLGEA United States
- YMAB United States
- Employees
- VLGEA N/A
- YMAB N/A
- Industry
- VLGEA Food Chains
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- VLGEA Consumer Staples
- YMAB Health Care
- Exchange
- VLGEA Nasdaq
- YMAB Nasdaq
- Market Cap
- VLGEA 501.1M
- YMAB 270.5M
- IPO Year
- VLGEA N/A
- YMAB 2018
- Fundamental
- Price
- VLGEA $33.14
- YMAB $4.73
- Analyst Decision
- VLGEA
- YMAB Buy
- Analyst Count
- VLGEA 0
- YMAB 11
- Target Price
- VLGEA N/A
- YMAB $19.64
- AVG Volume (30 Days)
- VLGEA 33.4K
- YMAB 431.5K
- Earning Date
- VLGEA 03-04-2025
- YMAB 03-04-2025
- Dividend Yield
- VLGEA 3.02%
- YMAB N/A
- EPS Growth
- VLGEA 3.71
- YMAB N/A
- EPS
- VLGEA 3.65
- YMAB N/A
- Revenue
- VLGEA $2,281,980,000.00
- YMAB $87,685,000.00
- Revenue This Year
- VLGEA N/A
- YMAB $20.07
- Revenue Next Year
- VLGEA N/A
- YMAB $8.76
- P/E Ratio
- VLGEA $9.08
- YMAB N/A
- Revenue Growth
- VLGEA 3.96
- YMAB 3.38
- 52 Week Low
- VLGEA $24.57
- YMAB $4.25
- 52 Week High
- VLGEA $35.34
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- VLGEA 53.18
- YMAB 32.27
- Support Level
- VLGEA $32.40
- YMAB $4.62
- Resistance Level
- VLGEA $34.48
- YMAB $5.03
- Average True Range (ATR)
- VLGEA 0.93
- YMAB 0.38
- MACD
- VLGEA 0.16
- YMAB -0.01
- Stochastic Oscillator
- VLGEA 65.64
- YMAB 31.37
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.